Answer
Yes, diarrhoea is a very common side effect of ibrutinib (Imbruvica) in patients with B-cell malignancies, meaning it affects at least 1 in 10 patients.
Sources for this answer
- IMBRUVICA 140 mg film-coated tablets (Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.8 Undesirable effects · Version 25Document updated
Sources checked